Although recently introduced infection markers such as procalcitonin, several cytokines and markers like endothelin-1, copeptin and pro-adrenomedullin show promising results in risk assessment and outcome prediction the implementation of these “new” infection markers is hampered by validation, costs and accessibility. This evidence concerns the gene EDN1 and infection.